The HIV diagnostics test market is witnessing significant growth attributed to rising incidences of HIV infections globally. HIV diagnostics tests help detect the presence of HIV antibodies or antigens in the blood, enabling early diagnosis and appropriate clinical management. Rapid HIV tests offer cost-effective point-of-care testing without laboratory instrumentation within 20 minutes, expanding accessibility.
The Global HIV Diagnostics Market is estimated to be valued at US$ 4,263.62 million in 2024 and is expected to exhibit a CAGR of 9.0% over the forecast period 2023 to 2030. Diagnosing HIV early enables timely treatment interventions that help reduce the risk of developing AIDS as well as spreading the infection. There is a growing need for HIV screening among high-risk groups like men who have sex with men, people with multiple sexual partners, and injection drug users.
Key Takeaways
Key Players: Key players operating in the HIV diagnostics test market are Abbott, Bio-Rad Laboratories, Inc., Hologic, Inc., Siemens Healthineers, Roche AG, Beckman Coulter Inc., OraSure Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems, Inc., Zyomyx Incorporation, Bristol –Myers Squibb, Janssen Pharmaceutica NV, QIAGEN N.V., and ViiV Healthcare Ltd.
Growing Demand: Rising demand for HIV diagnostics from public health organizations to provide testing to high-risk populations is positively impacting market revenues. The increasing availability of rapid self-testing kits will further boost mass testing initiatives.
Global Expansion: Key market players are investing in expanding their geographical footprint in high potential emerging markets. Strategic collaborations with local distributors are helping players penetrate developing Asian and African countries with a high burden of HIV.
Market Key Trends
One of the key trends in the HIV diagnostics market is the rise in blood screening. Mandatory blood screening for HIV at blood banks is being implemented in many countries to ensure a safe blood supply. Integration of advanced technologies like biochips for multiplex detection of HIV and other pathogens is another emerging trend. Miniaturization of tests for use in resource-constrained settings will further drive the decentralized testing revolution.
Porter’s Analysis
Threat of new entrants: High costs linked with new tests development processes and regulations to enter the market acts as a barrier.
Bargaining power of buyers: Large diagnostic companies and healthcare providers negotiate pricing and rebates with test developers.
Bargaining power of suppliers: Suppliers of raw materials and diagnostic kits have limited influence over pricing due to large buyer base.
Threat of new substitutes: New generation diagnostic tests pose threat of substitution due to improved accuracy and efficiency.
Competitive rivalry: Large players continually invest in R&D to launch innovative products and gain market share from competitors.
Geographical regions contributing to major HIV Diagnostics test market share are North America and Europe. In North America, U.S. holds the highest value share owing to large number of diagnosed patients and widespread adoption of advanced tests. Europe follows next supported by ongoing government funding for HIV prevention and improved access to screening.
South and East Asia regions are expected to witness fastest market growth during the forecast period. Countries like India, China, Indonesia and Vietnam contribute significantly due to rising incidence of HIV infections. Government initiatives in these nations encourage regular screening through low cost tests offered at local clinics and hospitals. Growing public awareness about HIV also boosts early detection rate thereby accelerating diagnostic test adoption.
No comments:
Post a Comment